The Role of the Endocannabinoid Signaling System in the Pathophysiology of Asthma and Obesity

Cover Page
  • Authors: Kytikovа O.Y.1, Novgorodtseva T.P.1, Denisenko Y.K.1, Antonyuk M.V.1, Gvozdenko T.A.1
  • Affiliations:
    1. Vladivostok Branch of Far Eastern Scientific Center of Physiology and Pathology of Respiration ― Institute of Medical Climatology and Rehabilitative Treatment, Vladivostok, Russian Federation
  • Issue: Vol 74, No 3 (2019)
  • Pages: 200-209
  • Section: РATHOPHYSIOLOGY: CURRENT ISSUES
  • URL: https://vestnikramn.spr-journal.ru/jour/article/view/1133
  • DOI: https://doi.org/10.15690/vramn1133
  • Cite item
Open Access Open Access
Restricted Access Subscription or Fee Access

Abstract


Bronchial asthma (BA) and obesity are one of the major modern problem, requiring the development of an effective therapeutic strategy. The frequent combination of these diseases in one patient indicates the general pathophysiological mechanisms and future study for targeted drug exposure are needed. The endocannabinoid system is involved in a variety of physiological and pathological processes and can be considered as a general mechanism and a potential therapeutic target in asthma and obesity, the receptors of the system are expressed in many central and peripheral tissues. This signal system modulates the functions of the autonomic nervous system, immune system and microcirculation, plays an important role in the regulation of energy balance, metabolism of carbohydrates and lipids. The main research aimed at studying the functioning of this system was focused on neurology and psychiatry, while numerous scientific data demonstrate the importance of the participation of this system in the pathogenesis of other diseases. In particular, this system is involved in the mechanisms of obesity. The role of the endocannabinoid system in the pathogenesis of asthma is actively studied. The wide prevalence of the endocannabinoid signaling system and its regulatory role in the body opens up prospects for therapeutic effects in the treatment of asthma and obesity, as well as the possible phenotype of asthma, combined with obesity. The review is devoted to modern ideas about endocannabinoids, their receptors, mechanisms of action and their role in the pathophysiology of asthma and obesity. The therapeutic prospects and difficulties associated with the use of endocannabinoids and phytocannabinoids in medicine are discussed.


Oksana Y. Kytikovа

Vladivostok Branch of Far Eastern Scientific Center of Physiology and Pathology of Respiration ― Institute of Medical Climatology and Rehabilitative Treatment, Vladivostok, Russian Federation

Author for correspondence.
Email: kytikova@yandex.ru
ORCID iD: 0000-0001-5018-0271

Russian Federation

MD, PhD, Professor.

73G, Russkaya street, 690105 Vladivostok; tel./fax: +7 (423) 278-82-01.

SPIN-код: 3006-5614

Tatyana P. Novgorodtseva

Vladivostok Branch of Far Eastern Scientific Center of Physiology and Pathology of Respiration ― Institute of Medical Climatology and Rehabilitative Treatment, Vladivostok, Russian Federation

Email: nauka@niivl.ru
ORCID iD: 0000-0002-6058-201X

Russian Federation

PhD, Professor.

73G, Russkaya street, 690105 Vladivostok.

SPIN-код: 5888-6099

Yuliya K. Denisenko

Vladivostok Branch of Far Eastern Scientific Center of Physiology and Pathology of Respiration ― Institute of Medical Climatology and Rehabilitative Treatment, Vladivostok, Russian Federation

Email: karaman@inbox.ru
ORCID iD: 0000-0003-4130-8899

Russian Federation

PhD.

73G, Russkaya street, 690105 Vladivostok.

SPIN-код: 4997-3432

Marina V. Antonyuk

Vladivostok Branch of Far Eastern Scientific Center of Physiology and Pathology of Respiration ― Institute of Medical Climatology and Rehabilitative Treatment, Vladivostok, Russian Federation

Email: antonyukm@mail.ru
ORCID iD: 0000-0002-2492-3198

Russian Federation

MD, PhD, Professor.

73G, Russkaya street, 690105 Vladivostok.

SPIN-код: 3446-4852

Tatyana A. Gvozdenko

Vladivostok Branch of Far Eastern Scientific Center of Physiology and Pathology of Respiration ― Institute of Medical Climatology and Rehabilitative Treatment, Vladivostok, Russian Federation

Email: vfdnz@mail.ru
ORCID iD: 0000-0002-6413-9840

Russian Federation

MD, PhD, Professor.

73G, Russkaya street, 690105 Vladivostok.

SPIN-код: 7869-1692

  1. Кытикова О.Ю., Гвозденко Т.А., Антонюк М.В. Современные аспекты распространенности хронических бронхолегочных заболеваний // Бюллетень физиологии и патологии дыхания. ― 2017. ― Т.64. ― С. 94–100. doi: 10.12737/article_5936346fdfc1f3.32482903.
  2. Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma; 2018. Available from: https://ginasthma.org/wp-content/uploads/2019/01/2018-GINA.pdf.
  3. WHO. Follow-up to the political declaration of the High-level meeting of the General Assembly on the prevention and control of non-communicable diseases. Geneva, Switzerland: World Health Assembly, 66; 2013. Available from: https://apps.who.int/iris/handle/10665/150161.
  4. Кытикова О.Ю., Антонюк М.В., Гвозденко Т.А., Новгородцева Т.П. Метаболические аспекты взаимосвязи ожирения и бронхиальной астмы // Ожирение и метаболизм. ― 2018. ― Т.15. ― №4. ― С. 9−14. doi: 10.14341/omet9578.
  5. Huang F, Del-Río-Navarro BE, Torres-Alcántara S, et al. Adipokines, asymmetrical dimethylarginine, and pulmonary function in adolescents with asthma and obesity. J Asthma. 2017;54(2):153–161. doi: 10.1080/02770903.2016.1200611.
  6. Караман Ю.К., Лобанова Е.Г. Эндоканнабиноиды и эйкозаноиды: биосинтез, механизмы их взаимосвязи, роль в иммунных процессах // Медицинская иммунология. ― 2013. ― Т.15. ― №2. ― С. 119–130.
  7. Denisenko YK, Lobanova EG, Novgorodtseva TP, et al. The role of arachidonic acid metabolites (endocannabinoids and eicosanoids) in the immune processes: a review. Int J Chem Biomed Sci. 2015;1(3):70–78.
  8. Wu J. Cannabis, cannabinoid receptors, and endocannabinoid system: yesterday, today, and tomorrow. Acta Pharmacol Sin. 2019;40(3):297–299. doi: 10.1038/s41401-019-0210-3.
  9. Fraguas-Sánchez AI, Martín-Sabroso C, Torres-Suárez AI. Insights into the effects of the endocannabinoid system in cancer: a review. British J Pharmacol. 2018;175(13):2566–2580. doi: 10.1111/bph.14331.
  10. Maurya N, Velmurugan BK. Therapeutic applications of cannabinoids. Chem Biol Interact. 2018;293:77–88. doi: 10.1016/j.cbi.2018.07.018.
  11. García-Martín A, Garrido-Rodríguez M, Navarrete C, et al. Cannabinoid derivatives acting as dual PPARγ/CB2 agonists as therapeutic agents for systemic sclerosis. Biochem Pharmacol. 2019;163:321–334. doi: 10.1016/j.bcp.2019.02.029.
  12. Ghosh M, Naderi S. Cannabis and cardiovascular disease. Curr Atheroscler Rep. 2019;21(6):21. doi: 10.1007/s11883-019-0783-9.
  13. Mlost J, Wąsik A, Starowicz K. Role of endocannabinoid system in dopamine signalling within the reward circuits affected by chronic pain. Pharmacol Res. 2019;143:40–47. doi: 10.1016/j.phrs.2019.02.029.
  14. Ruiz de Azua I, Lutz B. Multiple endocannabinoid-mediated mechanisms in the regulation of energy homeostasis in brain and peripheral tissues. Cell Mol Life Sci. 2019;76(7):1341–1363. doi: 10.1007/s00018-018-2994-6.
  15. Ferrini ME, Hong S, Stierle A, et al. CB2 receptors regulate natural killer cells that limit allergic airway inflammation in a murine model of asthma. Allergy. 2017;72(6):937–947. doi: 10.1111/all.13107.
  16. Shang VC, O’Sullivan SE, Kendall DA, Roberts RE. The endogenous cannabinoid anandamide increases human airway epithelial cell permeability through an arachidonic acid metabolite. Pharmacol Res. 2016;105:152–163. doi: 10.1016/j.phrs.2016.01.023.
  17. Le Boisselier R, Alexandre J, Lelong-Boulouard V, Debruyne D. Focus on cannabinoids and synthetic cannabinoids. Clin Pharmacol Ther. 2017;101:220–229. doi: 10.1002/cpt.563.
  18. Turcotte C, Chouinard F, Lefebvre JS, Flamand N. Regulation of inflammation by cannabinoids, the endocannabinoids 2-arachidonoyl-glycerol and arachidonoyl-ethanolamide, and their metabolites. J Leuk Biol. 2015;97(6):1049–1070. doi: 10.1189/jlb.3RU0115-021R.
  19. Martín-Saldaña S, Trinidad A, Ramil E. Spontaneous cannabinoid receptor 2 (CB2) expression in the cochlea of adult albino rat and its up-regulation after cisplatin treatment. PLoS One. 2016;11(8):e0161954. doi: 10.1371/journal.pone.0161954.
  20. Mazier W, Saucisse N, Gatta-Cherifi B, Cota D. The endocannabinoid system: pivotal orchestrator of obesity and metabolic disease. Trends Endocrinol Metab. 2015;26:524–537. doi: 10.1016/j.tem.2015.07.007.
  21. De Luca MA, Solinas M, Bimpisidis Z, et al. Cannabinoid facilitation of behavioral and biochemical hedonic taste responses. Neuropharmacology. 2012;63:161–168. doi: 10.1016/j.neuropharm.2011.10.018.
  22. Hillard CJ. Circulating endocannabinoids: from whence do they come and where are they going? Neuropsychopharmacology. 2018;43(1):155–172. doi: 10.1038/npp.2017.130.
  23. Silvestri C, Di Marzo V. The endocannabinoid system in energy homeostasis and the etiopathology of metabolic disorders. Cell Metab. 2013;17(4):475–490. doi: 10.1016/j.cmet.2013.03.001.
  24. Motwani MP, Bennett F, Norris PC. Potent anti-inflammatory and pro-resolving effects of anabasum in a human model of self-resolving acute inflammation. Clin Pharmacol Ther. 2018;8:47(2):S78. doi: 10.1002/cpt.980.
  25. Lobanova EG. Role of endocannabinoid receptors in immune response regulation. Medical Immunol. 2014;14(3):189–194. doi: 10.15789/1563-0625-2012-3-189-194.
  26. Morales P, Isawi I, Reggio PH. Towards a better understanding of the cannabinoid-related orphan receptors GPR3, GPR6, and GPR12. Drug Metab Rev. 2018;50(1):74–93. doi: 10.1080/03602532.2018.1428616.
  27. Carlier J, Diao X, Scheidweiler KB, Huestis MA. Distinguishing intake of new synthetic cannabinoids ADB-PINACA and 5F-ADB-PINACA with human hepatocyte metabolites and high-resolution mass spectrometry. Clin Chem. 2017;63(5):1008–1021. doi: 10.1373/clinchem.2016.267575.
  28. Winter Z, Buhala A, Ötvös F, et al. Functionally important amino acid residues in the transient receptor potential vanilloid 1 (TRPV1) ion channelan overview of the current mutational data. Mol Pain. 2013;9:30. doi: 10.1186/1744-8069-9-30.
  29. Muller C, Morales P, Reggio PH. Cannabinoid ligands targeting TRP channels. Front Mol Neurosci. 2019;11:487. doi: 10.3389/fnmol.2018.00487.
  30. Petrosino S, Di Marzo V. The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations. Br J Pharmacol. 2017;174(11):1349–1365. doi: 10.1111/bph.13580.
  31. Aghazadeh Tabrizi M, Baraldi PG, Baraldi S, et al. Medicinal chemistry, pharmacology, and clinical implications of trpv1 receptor antagonists. Med Res Rev. 2017;37(4):936–983. doi: 10.1002/med.21427.
  32. Ibsen MS, Connor M, Glass M. Cannabinoid CB1 and CB2 receptor signaling and bias. Cannabis Cannabinoid Res. 2017;2(1):48–60. doi: 10.1089/can.2016.0037.
  33. Hillard CJ. The endocannabinoid signaling system in the CNS: a primer. Int Rev Neurobiol. 2015;125:1–47. doi: 10.1016/bs.irn.2015.10.001.
  34. Di Marzo V. New approaches and challenges to targeting the endocannabinoid system. Nature Reviews Drug Discovery. 2018;17(9):623–639. doi: 10.1038/nrd.2018.115.
  35. Baggelaar MP, Maccarrone M, van der Stelt M. 2-Arachidonoylglycerol: a signaling lipid with manifold actions in the brain. Prog Lipid Res. 2018;71:1–17. doi: 10.1016/j.plipres.2018.05.002.
  36. Urquhart P, Nicolaou A, Woodward DF. Endocannabinoids and their oxygenation by cyclooxygenases, lipoxygenases and other oxygenases. Biochim Biophys Acta. 2015;1851:366–376. doi: 10.1016/j.bbalip.2014.12.015.
  37. Matias I, Gatta-Cherifi B, Tabarin A, et al. Endocannabinoids measurement in human saliva as potential biomarker of obesity. PLoS ONE. 2012;7(7):e42399. doi: 10.1371/journal.pone.0042399.
  38. Krumbholz A, Anielski P, Reisch N, et al. Diagnostic value of concentration profiles of glucocorticosteroids and endocannabinoids in hair. Ther Drug Monit. 2013;35:600–607. doi: 10.1097/FTD.0b013e3182953e43.
  39. Lam PM, Marczylo TH, Konje JC. Simultaneous measurement of three N-acylethanolamides in human bio-matrices using ultra performance liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem. 2010;398:2089–2097. doi: 10.1007/s00216-010-4103-z.
  40. Heinitz S, Basolo A, Piaggi P, et al. Peripheral endocannabinoids associated with energy expenditures in Native Americans of Southwestern heritage. J Clin Endocrinol Metab. 2018;103:1077–1087. doi: 10.1210/jc.2017-02257.
  41. Cao JК, Kaplan J, Stella N. ABHD6: its place in endocannabinoid signaling and beyond. Trends Pharmacol Sci. 2019;40(4):267–277. doi: 10.1016/j.tips.2019.02.002.
  42. Freitas HR, Isaac AR, Malcher-Lopes R, et al. Polyunsaturated fatty acids and endocannabinoids in health and disease. Nutr Neurosci. 2018;21(10):695–714. doi: 10.1080/1028415X.2017.1347373.
  43. Simopoulos AP. An increase in the omega-6/omega-3 fatty acid ratio increases the risk for obesity. Nutrients. 2016;8(3):128. doi: 10.3390/nu8030128.
  44. Hindmarch CC, Ferguson AV. Physiological roles for the subfornical organ: a dynamic transcriptome shaped by autonomic state. J Physiol. 2016;594(6):1581–1589. doi: 10.1113/JP270726.
  45. Verty AN, Allen AM, Oldfield BJ. The effects of rimonabant on brown adipose tissue in rat: implications for energy expenditure. Obesity (Silver Spring). 2009;17(2):254–261. doi: 10.1038/oby.2008.509.
  46. Argueta DA, DiPatrizio NV. Peripheral endocannabinoid signaling controls hyperphagia in western diet-induced obesity. Physiol Behav. 2017;171:32–39. doi: 10.1016/j.physbeh.2016.12.044.
  47. Amato G, Khan NS, Maitra R. A patent update on cannabinoid receptor 1 antagonists (2015–2018). Expert Opin Ther Pat. 2019;29(4):261–269. doi: 10.1080/13543776.2019.1597851.
  48. Abdulnour RE, Dalli J, Colby JK, et al. Maresin 1 biosynthesis during platelet-neutrophil interactions is organ-protective. Proc Natl Acad Sci U S A. 2014;111(46):16526–16531. doi: 10.1073/pnas.1407123111.
  49. Monteleone AM, Di Marzo V, Monteleone P, et al. Responses of peripheral endocannabinoids and endocannabinoid-related compounds to hedonic eating in obesity. Eur J Nutr. 2016;55(4):1799–1805. doi: 10.1007/s00394-016-1153-9.
  50. Kuipers EN, Kantae V, Maarse BC, et al. High fat diet increases circulating endocannabinoids accompanied by increased synthesis enzymes in adipose tissue. Front Physiol. 2019;9:1913. doi: 10.3389/fphys.2018.01913.
  51. Gatta-Cherifi B, Matias I, Vallee M, et al. Simultaneous postprandial deregulation of the orexigenic endocannabinoid anandamide and the anorexigenic peptide YY in obesity. Int J Obes (Lond). 2012;36(6):880–885. doi: 10.1038/ijo.2011.165.
  52. Wei D, Lee D, Li D. A role for the endocannabinoid 2-arachidonoyl-sn-glycerol for social and high-fat food reward in male mice. Psychopharmacology (Berl). 2016;233(10):1911–1919. doi: 10.1007/s00213-016-4222-0.
  53. Corrado A, Battle M, Wise SK, et al. Endocannabinoid receptor CB2R is significantly expressed in aspirin-exacerbated respiratory disease: a pilot study. Int Forum Allergy Rhinol. 2018;8(10):1184–1189. doi: 10.1002/alr.22163.
  54. Zhou J, Burkovskiy I, Yang Н, et al. CB2 and GPR55 receptors as therapeutic targets for systemic immune dysregulation. Front Pharmacol. 2016;7:264. doi: 10.3389/fphar.2016.00264.
  55. Larose MC, Turcotte C, Chouinard F, et al. Mechanisms of human eosinophil migration induced by the combination of IL5 and the endocannabinoid 2-arachidonoyl-glycerol. J Allergy Clin Immunol. 2014;133(5):1480–1482. doi: 10.1016/j.jaci.2013.12.1081.
  56. Frei RB, Luschnig P, Parzmair GP, et al. Cannabinoid receptor 2 augments eosinophil responsiveness and aggravates allergen-induced pulmonary inflammation in mice. Allergy. 2016;71(7):944–956. doi: 10.1111/all.12858.
  57. Espinosa-Riquer ZP, Ibarra-Sánchez A, Vibhushan S, et al. TLR4 receptor induces 2-AG-dependent tolerance to lipopolysaccharide and trafficking of CB2 receptor in mast cells. J Immunol. 2019;202(8):2360–2371. doi: 10.4049/jimmunol.1800997.
  58. Hoyt AE, Borish L, Gurrola J, Payne SC. Allergic fungal rhinosinusitis. J Allergy Clin Immunol Pract. 2016;4(4):599–604. doi: 10.1016/j.jaip.2016.03.010.
  59. Oláh A, Szekanecz Z, Bíró T. Targeting cannabinoid signaling in the immune system: “High”-ly exciting questions, possibilities, and challenges. Front Immunol. 2017;8:1487. doi: 10.3389/fimmu.2017.01487.
  60. Smith SG, Chen R, Kjarsgaard M, et al. Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia. J Allergy Clin Immunol. 2016;137(1):75–86. doi: 10.1016/j.jaci.2015.05.037.
  61. Roediger B, Weninger W. Group 2 innate lymphoid cells in the regulation of immune responses. Adv Immunol. 2015;125:111–154. doi: 10.1016/bs.ai.2014.09.004.
  62. Nussbaum JC, Van Dyken SJ, von Moltke J, et al. Type 2 innate lymphoid cells control eosinophil homeostasis. Nature. 2013;502(7470):245–248. doi: 10.1038/nature12526.
  63. Bozkurt TE, Kaya Y, Durlu-Kandilci NT, et al. The effect of cannabinoids on dinitrofluorobenzene-induced experimental asthma in mice. Respir Physiol Neurobiol. 2016;231:7–13. doi: 10.1016/j.resp.2016.05.012.
  64. Scott H, Gibson P, Garg M, et al. Sex hormones and systemic inflammation are modulators of the obese-asthma phenotype. Allergy. 2016;71(7):1037–1047. doi: 10.1111/all.12891.
  65. Shore SA. Obesity and asthma: possible mechanisms. J Allergy Clin Immunol. 2008;121(5):1087–1093. doi: 10.1016/j.jaci.2008.03.004.
  66. De Lima Azambuja R, da Costa Santos Azambuja L, Costa S, et al. Adiponectin in asthma and obesity: protective agent or risk factor for more severe disease? Lung. 2015;193(5):749–755. doi: 10.1007/s00408-015-9793-8.
  67. Song Y. Asthma, chronic obstructive pulmonary disease, and type 2 diabetes in the women’s health study. Diabetes Res Clin Pract. 2010;90(3):365–437. doi: 10.1016/j.diabres.2010.09.010.
  68. Sood A, Shore SA. Adiponectin, leptin, and resistin in asthma: basic mechanisms through population studies. J Allergy (Cairo). 2013;2013:785835. doi: 10.1155/2013/785835.
  69. Kalliomäki J, Segerdahl M, Webster L, et al. Evaluation of the analgesic efficacy of AZD1940, a novel cannabinoid agonist, on post-operative pain after lower third molar surgical removal. Scand J Pain. 2013;4(1):17–22. doi: 10.1016/j.sjpain.2012.08.004.
  70. Gertsch J. Cannabimimetic phytochemicals in the diet ― an evolutionary link to food selection and metabolic stress adaptation? Br J Pharmacol. 2017;174(11):1464–1483. doi: 10.1111/bph.13676.
  71. Sloan ME, Gowin JL, Ramchandani VA, et al. The endocannabinoid system as a target for addiction treatment: trials and tribulations. Neuropharmacology. 2017;124:73–83. doi: 10.1016/j.neuropharm.2017.05.031.

Views

Abstract - 82

PDF (Russian) - 0

Cited-By


PlumX



Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies